National Health Insurance Fund

Association between adherence patterns to antifibrotic therapy and survival in fibrotic interstitial lung disease: a nationwide Austrian health claims study

Antifibrotic therapies slow disease progression in patients with progressive fibrosing interstitial lung diseases (PF-ILD). However, long-term adherence is difficult to maintain mainly due to side effects. Real-world data on adherence and its association with prognosis are still...